Floatz logo

National Cancer Institute -4650, A Messenger Ribonucleic Acid -Based, Personalized Cancer Vaccine

Colon Cancer

National Cancer Institute (NCI)vaccinePhase 1/2Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
65/ 100

Competitive context

158 Active assets in the Colon Cancer cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Akeso
Phase 4A
Irinotecan
Fudan University
Phase 3BBB
Floxuridine
City of Hope Medical Center
Phase 2BBB
FLUOROURACILUM
Akeso
Phase 4BB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

National Cancer Institute -4650, A Messenger Ribonucleic Acid -Based, Personalized Cancer Vaccine is also rated in:

hepatocellular carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
malignant urinary system neoplasmDormant
CC
Indicative ·
45 / 100
View asset →
digestive system cancerDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →